How Psilocybin-Assisted Psychotherapy Works

Psilocybin-assisted psychotherapy combines a pharmacological effect (psilocybin activating serotonin 2A receptors and temporarily quieting the brain's default mode network) with a structured therapeutic framework of preparation, dosing, and integration. Neither element works well alone. This article explains both, in plain language, for patients considering this pathway.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334, on 2026-05-27.

Key takeaways

• Psilocybin is a 5-HT2A receptor agonist. Its psychedelic effects arise primarily from activating those receptors in the cortex.
• The default mode network (DMN), the brain's self-referential circuit, is quieted during the psilocybin experience. Research suggests this disruption loosens rigid thought patterns associated with depression [Carhart-Harris 2012].
• Psilocybin promotes neuroplasticity: growth of new dendritic spines and synaptic connections in ways comparable to ketamine [Ly 2018].
• The quality of the psychedelic experience, not just the drug itself, predicts therapeutic benefit [Roseman 2018].
• A three-phase structure (preparation, dosing, integration) is standard across published trials. The therapy is considered the container that makes the drug experience clinically useful.
• In Canada, legal patient access to psilocybin-assisted therapy requires Health Canada authorization on a case-by-case basis, initiated by a physician.

If you are considering psilocybin therapy through this pathway and want to understand whether it may be appropriate for your situation, book a free information call with ATMA CENA's clinical team.

What psilocybin does in the brain

Psilocybin is a prodrug. When you swallow it, the body converts it rapidly to psilocin. Psilocin is a serotonin 2A (5-HT2A) receptor agonist: it binds to and activates those receptors, which are concentrated in the cortex, the brain's outer layer responsible for perception, cognition, and self-referential thought.

The result is not simply "more serotonin." Activating 5-HT2A receptors in the cortex triggers a cascade of effects that temporarily reorganise how brain regions communicate with each other. Two of these effects are most relevant to the therapeutic model:

1. Default mode network suppression. The default mode network (DMN) is a set of midline brain regions, particularly the medial prefrontal cortex and posterior cingulate cortex, that are active when we are thinking about ourselves: ruminating, planning, judging, constructing narrative. In depression, the DMN is often overactive and tightly coupled, which researchers associate with the rigid, self-critical thought loops that characterise the illness.

Carhart-Harris and colleagues (2012) used fMRI to show that psilocybin significantly decreases activity in key DMN hub regions, and that the magnitude of this decrease predicted the intensity of the subjective psychedelic experience [Carhart-Harris 2012]. A follow-up study specifically in treatment-resistant depression (TRD) found that psilocybin produced marked post-treatment decreases in DMN activity and reduced the tight coupling between the medial prefrontal cortex and the posterior cingulate that characterises rumination [Carhart-Harris 2017].

The plain-language version: psilocybin temporarily loosens the grip of the self-critical mental habits that many people with depression recognise as a core part of their suffering.

2. Neuroplasticity. Psilocybin and other serotonergic psychedelics promote structural and functional neuroplasticity. Ly and colleagues (2018) demonstrated that psilocin increases neuritogenesis (growth of new neuronal branches) and spinogenesis (growth of new dendritic spines, the contact points between neurons), via TrkB, mTOR, and 5-HT2A signalling pathways, with effects comparable to ketamine [Ly 2018].

In plain language: the brain's capacity to form new connections appears to increase during and after the psilocybin experience. Integration therapy is designed to take advantage of this window of heightened plasticity to build new thought and behaviour patterns.

Why the therapeutic experience matters, not just the drug

The pharmacology above explains the biological substrate. But the quality of the psychedelic experience itself is also a predictor of therapeutic benefit, independent of the drug dose.

Roseman and colleagues (2018) analysed data from the Imperial College London TRD trial and found that "Oceanic Boundlessness" (a measure of the mystical or transcendent quality of the experience) and "Dread of Ego Dissolution" (acute psychological challenge) both independently predicted depression improvement at five weeks. Perceptual effects alone did not. The quality of the acute psychedelic experience appeared to be a key mediator of therapeutic outcome [Roseman 2018].

This finding has a practical implication for the therapy model: the therapeutic frame around the dosing session (set, setting, therapist presence, preparation) matters because it shapes the quality of the experience, which in turn predicts outcome. The drug is not doing the work alone.

The three-phase therapy structure

Published psilocybin trials use a consistent three-phase structure around the pharmacological experience. This structure is not decoration; it is the container that turns a drug effect into therapy.

Phase	Typical format	What it accomplishes
Preparation	2–3 sessions, 2–4 weeks before dosing	Therapeutic alliance, intentions, informed consent, set/setting orientation, safety planning, grounding skills
Dosing	1–2 sessions, 6–8 hours each	Pharmacological experience in a structured clinical environment; non-directive therapist presence
Integration	2–4 sessions, days to weeks after dosing	Meaning-making, translating experiential content into behavioural change, relapse prevention, processing difficult material

Preparation: building the container

Preparation is where the therapeutic alliance is formed, the patient is oriented to the physical and relational environment of dosing, and the consent process is completed. Patients learn grounding skills, such as breath and somatic anchoring, they can use during peak intensity. Safety planning covers emergency contacts, post-session rest, and explicit conversation about what to do if difficult content arises during dosing.

The therapist team for the dosing session ideally meets the patient during preparation, not for the first time on dosing day. Most published protocols use the same team across all three phases.

Dosing: non-directive presence

The dosing session is the longest and most intense phase. The therapist's primary role during dosing is non-directive presence: physically available and emotionally supportive, grounding when needed, not actively interpreting or psychoeducating. The patient's internal experience is the work; the therapist holds space for it.

Eye shades and curated music are standard. Eye shades support inward focus during peak intensity. Music is part of the therapeutic frame, not background; it is selected to support the emotional arc of the session. The "Hopkins playlist" (developed at Johns Hopkins) is widely used or adapted across published protocols.

Most published psilocybin trials use two trained therapists present during dosing (Carhart-Harris 2016 Lancet Psychiatry, Davis 2021 JAMA Psychiatry, Goodwin 2022 NEJM, Bogenschutz 2022 JAMA Psychiatry). The two-therapist model provides continuity of presence over a 6–8 hour session, clinical safety redundancy, and, in some protocols, a deliberate relational field created by two non-judging witnesses.

Integration: where change takes hold

Integration is where the acute experience becomes psychological and behavioural change. Therapists help patients translate experiential content (what arose, what felt important, what was unexpected) into language, narrative, and action. Difficult experiences (fear, grief, disorientation) are reframed as meaningful rather than simply distressing. Behavioural commitments are made explicit. For TRD or addiction, integration includes specific relapse-prevention planning.

The neuroplasticity window opened by psilocybin (see above) is most practically engaged in integration: building new cognitive patterns and habits while the brain's capacity for rewiring is elevated.

Manualized therapy frameworks across published trials

No single therapy manual is "the" psilocybin-assisted psychotherapy framework. Different trials have used different structured approaches:

• ACE (Accept-Connect-Embody): Imperial College, TRD (Carhart-Harris 2016, 2021). Acceptance-based, drawing from ACT. Non-directive during dosing; structured during preparation and integration.
• Supportive psychotherapy with CBT elements: Johns Hopkins MDD trial (Davis 2021). Psychoeducation, expectation-setting, goal-focused integration.
• MET + CBT: Bogenschutz 2022 alcohol use disorder trial. Psilocybin paired with 12 weeks of structured motivational enhancement and CBT, the same framework used in Project MATCH.
• Meaning-Centered Psychotherapy: Breitbart cancer protocol (drawing on Viktor Frankl's logotherapy). Developed for advanced-cancer patients with demoralization and existential distress.

The unifying principles across all these frameworks: three-phase structure, non-directive dosing presence, and structured integration.

How ATMA CENA supports patients on this pathway

Psilocybin is a restricted drug under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin-assisted therapy in Canada requires Health Canada authorization on a case-by-case basis, initiated by the patient's prescribing physician, and it is not guaranteed. Authorization is generally considered for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness.

ATMA CENA does not initiate the request for authorization and does not itself administer psilocybin; that authorization is initiated and held by the prescribing physician. Where a patient has physician-led authorization in place, ATMA CENA's clinical team can support the psychotherapy wraparound, the preparation and integration work described above, in coordination with the prescribing physician.

Through our CoCare program, we can partner with your therapist if they have the appropriate training and build a service agreement with us. This lets an existing therapeutic relationship continue while the preparation and integration structure is coordinated with ATMA CENA's clinical team. Learn more about the CoCare model.

Book a free information call to discuss whether this pathway and ATMA CENA's support model may fit your situation.

Frequently asked questions

What is the neuroscience behind psilocybin's effects?

Psilocybin converts to psilocin in the body, which activates 5-HT2A serotonin receptors in the cortex. This temporarily quiets the default mode network (the brain's self-referential rumination circuit), disrupts rigid thought patterns associated with depression, and promotes neuroplasticity, the growth of new synaptic connections. These biological effects create a window of psychological flexibility that structured therapy is designed to work within.

Why does the therapeutic frame matter if the drug is doing the neurological work?

Because the quality of the psychedelic experience predicts therapeutic benefit, and the therapeutic frame shapes the quality of the experience. Research by Roseman and colleagues (2018) found that the mystical or transcendent quality of the experience, not just perceptual effects, predicted depression outcomes at five weeks. Set, setting, therapist presence, and preparation all contribute to that quality.

What does "non-directive presence" mean for the therapist?

During peak dosing intensity, the therapist is physically present and emotionally available but does not actively interpret, guide, or psychoeducate. The patient's internal process is the primary therapeutic work; the therapist holds space for it. The therapist becomes more conversational as the experience comes down and the patient begins spontaneous meaning-making.

Why are eye shades and music used?

Eye shades support inward focus during peak intensity, redirecting attention away from the external environment and toward the internal experience. Curated music, often manualized across published trials (the "Hopkins playlist" is widely used), is part of the therapeutic frame, designed to support the emotional arc of the session, not as background noise.

What is integration therapy and how is it different from regular psychotherapy?

Integration sessions specifically focus on translating the dosing experience into psychological and behavioural change. They work with the experiential content that arose during dosing (what felt important, what was unexpected, what was difficult) and connect it to the patient's stated goals and life situation. This is distinct from general psychotherapy, which does not follow a pharmacological experience.

Is psilocybin available in Canada?

Legal patient access to psilocybin-assisted therapy in Canada requires Health Canada authorization on a case-by-case basis, initiated by a physician. Authorization is not guaranteed and is generally considered for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness.

How many integration sessions are typical?

Published trial protocols use 2–4 integration sessions following each dosing event. Some patients benefit from longer ongoing integration with their existing therapist; ATMA CENA's CoCare model supports this continuity.

What if I had a difficult experience during dosing?

Difficult experiences are common and, in the published trial literature, often associated with positive outcomes when properly integrated. Integration therapy is where challenging content is reframed and metabolised. Preparation includes explicit safety planning and grounding skills for this reason.

Compliance disclaimer

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada authorization on a case-by-case basis, initiated by a physician, and it is not guaranteed. Psilocybin authorization is generally considered for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA authorization is generally considered for adults with PTSD. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognised leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritises effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Carhart-Harris RL, Erritzoe D, Williams T, et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS, 109(6), 2138–2143. PMID: 22308440. https://pubmed.ncbi.nlm.nih.gov/22308440/
2. Ly C, Greb AC, Cameron LP, et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. PMID: 29898390. https://pubmed.ncbi.nlm.nih.gov/29898390/
3. Roseman L, Nutt DJ, Carhart-Harris RL. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8:974. PMID: 29387009. https://pubmed.ncbi.nlm.nih.gov/29387009/
4. Carhart-Harris R, Roseman L, Bolstridge M, et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7(1), 13187. PMID: 29032520. https://pubmed.ncbi.nlm.nih.gov/29032520/
5. Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7), 619–627. PMID: 27210031. https://pubmed.ncbi.nlm.nih.gov/27210031/
6. Davis AK, Barrett FS, May DG, et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. PMID: 33146667. https://pubmed.ncbi.nlm.nih.gov/33146667/
7. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637–1648. PMID: 36322843. https://pubmed.ncbi.nlm.nih.gov/36322843/
8. Bogenschutz MP, Ross S, Bhatt S, et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry, 79(10), 953–962. PMID: 36001306. https://pubmed.ncbi.nlm.nih.gov/36001306/
9. Health Canada. (2022). Notice: requests involving psychedelic-assisted psychotherapy reviewed for case-by-case authorization. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
10. ATMA CENA, Information Call: https://atmacena.com/information-call/
11. ATMA CENA, CoCare: https://atmacena.com/cocare/

Related articles in this cluster

• What Is Psilocybin Therapy?